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Abstract
Background: Dynamic models of infection transmission can project future disease burden within a population.
Few dynamic measles models have been developed for low-income countries, where measles disease burden is
highest. Our objective was to review the literature on measles epidemiology in low-income countries, with a
particular focus on data that are needed to parameterize dynamic models.
Methods: We included age-stratified case reporting and seroprevalence studies with fair to good sample sizes for
mostly urban African and Indian populations. We emphasized studies conducted before widespread immunization.
We summarized age-stratified attack rates and seroprevalence profiles across these populations. Using the study
data, we fitted a “representative” seroprevalence profile for African and Indian settings. We also used a catalytic
model to estimate the age-dependent force of infection for individual African and Indian studies where
seroprevalence was surveyed. We used these data to quantify the effects of population density on the basic
reproductive number R0.
Results: The peak attack rate usually occurred at age 1 year in Africa, and 1 to 2 years in India, which is earlier
than in developed countries before mass vaccination. Approximately 60% of children were seropositive for measles
antibody by age 2 in Africa and India, according to the representative seroprevalence profiles. A statistically
significant decline in the force of infection with age was found in 4 of 6 Indian seroprevalence studies, but not in
2 African studies. This implies that the classic threshold result describing the critical proportion immune (pc)
required to eradicate an infectious disease, pc = 1-1/R0, may overestimate the required proportion immune to
eradicate measles in some developing country populations. A possible, though not statistically significant, positive
relation between population density and R0 for various Indian and African populations was also found. These
populations also showed a similar pattern of waning of maternal antibodies. Attack rates in rural Indian populations
show little dependence on vaccine coverage or population density compared to urban Indian populations.
Estimated R0 values varied widely across populations which has further implications for measles elimination.
Conclusions: It is possible to develop a broadly informative dynamic model of measles transmission in low-
income country settings based on existing literature, though it may be difficult to develop a model that is closely
tailored to any given country. Greater efforts to collect data specific to low-income countries would aid in control
efforts by allowing highly population-specific models to be developed.
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Measles is a highly contagious disease, spreading espe-
cially rapidly in populations that are dense and/or exhi-
bit low immunity [1]. The main natural carrier for
measles is humans (though it is possible for some pri-
mates to acquire infection) [2], and there are no known
long-term reservoirs for the virus [3]. Hence, an effec-
tive method of prevention is prophylactic vaccination.
Measles can be prevented by a relatively inexpensive
and effective vaccine, and yet measles remains one of
the leading causes of death in children [4]. Measles
caused an estimated 242,000 deaths globally in 2006,
95% of them occurring in countries with high-level pov-
erty and poor health infrastructure [5]. The severity of
measles can range from mild symptoms to severe infec-
tion, but it is usually the complications following infec-
tion that lead to death or disability [3,5]. Though
vitamin A supplementation does not seem to have any
impact on incidence, duration, or prevalence of infec-
tious diseases [6], it has been shown numerous times to
reduce the severity and thus mortality in infectious dis-
eases–including measles and its complications–because
of its necessary role in the immune system [2]. Conver-
sely, there have been differing views as to whether or
not improving the overall nutritional status of children
would reduce the risk of mortality. Review papers by
Aaby [7,8] and Singh et al ([9]) found little or no rela-
tion between malnutrition and measles related deaths in
Africa or India, respectively. However, though Aaby
mentions vitamin A as a possible factor in measles
related deaths, he says other causes of severe complica-
tions may dominate over vitamin A deficiency [7]. Singh
et al also recognized the significance of vitamin A but
none of the papers included in their review explicitly
took vitamin A supplementation into account.
A live attenuated measles vaccine has existed since the
mid 1960s [3]. However, strong and coordinated global
action to significantly reduce measles mortality did not
occur until the launch of the Measles Initiative in 2001.
Since then, measles deaths have been reduced by 68%
worldwide and 91% in Africa [10]. Much of this reduc-
tion has been achieved through Supplementary Immuni-
zation Activities (SIAs), which are large-scale campaigns
aimed at vaccinating all children under a certain age. In
other cases, routine immunization (RI) is being
improved either by increasing the coverage of the first
dose of measles vaccine, or by introducing a second
dose in countries where first-dose coverage is already
relatively strong [11]. However, while coverage has
reached high levels in many countries, it remains low
and relatively stagnant in others. Moreover, the optimal
timing of SIAs and the optimal criterion for introducing
the second dose of routine vaccination are not known
because this depends partly on eventual measles inci-
dence and measles disease burden under the various
alternative vaccination strategies being considered.
Hence, modelling exercises intended to project optimal
vaccination “second opportunity” strategies in this set-
ting may prove valuable.
Although future measles incidence and disease burden
cannot be known precisely, they can be projected by use
of a dynamic model. Dynamic models (e.g., age-struc-
tured compartmental models) incorporate transmission
mechanisms and thus can describe how incidence
evolves due to changes in factors such as demography
and vaccine coverage [12]. Dynamic models allow us to
analyse the epidemiology of a disease within a popula-
tion and experiment with various vaccination strategies
“in silico“ to determine which one would be optimal
from a given perspective (e.g. public health, cost-
effectiveness).
Ideally, dynamic models are parameterized with data
that are specific to the study population. However,
measles epidemiology can vary across populations,
which in turn provide implications for how vaccination
programmes should be designed [13]. In the 1960s,
Morley et al recognized and documented important dif-
ferences between the epidemiology of measles in devel-
oping countries compared to measles in the UK and
North America, since at least the 1920s [14]. Suggested
reasons for this have included differences in living con-
ditions, nutrition, demography (birth rate), and social/
cultural behavioural differences [14]. Because of this,
models intended for developed countries are not neces-
sarily applicable for developing countries [13]. For
example, models developed by Babad et al [15] and
C v j e t a n o v i ce ta l[ 1 6 ]b o t ha ssume the epidemiology of
measles in England and Wales, with a mean age of
infection in children of approximately 5 years. This has
been thought to reflect the fact that children were rela-
tively isolated from other children until the start of
school. In contrast, developing countries have a much
lower age at infection, as described by McLean et al
[14], and specific social and cultural factors that may
explain this have been identified [17], such as larger
family sizes and greater mixing from a younger age.
This paper provides a summary of data needed to
develop a dynamic model of measles transmission in
Indian and African populations, such as the percent
infected by age (age-stratified attack rate) and age-strati-
fied seroprevalence profiles. We review included studies
individually, discussing their design, limitations, and
major conclusions. We use these studies to summarize
attack rates and seroprevalence and make deductions
about transmissibility in African versus Indian popula-
tions. We summarize the broad features of measles
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“representative” age-stratified seroprevalence profile. We
also use the data to quantify the effects of population
density on transmissibility measures such as the basic
reproductive number R0. Finally, we use a catalytic
model to compute age-dependent force of infection for
individual populations where seroprevalence studies
were available.
Methods
Age-stratified attack rates (i.e. the percent of individuals
infected in each age group in a given outbreak or over a
longer period of time) and seroprevalence are needed to
determine susceptibility levels and transmission rates
within a population. These measures can vary between
rural and urban populations as well as between coun-
tries, and over time in a given population. Ideally, one
has sufficient data to allow analysis of each population
individually; in practice, however, data availability can be
limited for any given population [18]. Here, we summar-
ize available data for a number of low-income countries
to investigate whether there are any general trends that
apply in most or all low-income countries.
The basic reproduction number R0–the average num-
ber of secondary infections produced by an infected per-
son in a totally susceptible population–is an important
epidemiological measure that defines a threshold for
whether an infectious disease can invade a population.
When R0 is above 1, each infectious person can infect
more than one person in a totally susceptible popula-
tion, and hence it is possiblef o rt h ei n f e c t i o u sd i s e a s e
to invade [19]. Conversely when R0 is below 1, an infec-
tious disease cannot invade a totally susceptible popula-
tion. R0 also plays a role in indicating how easily an
endemic infectious disease can be controlled and/or era-
dicated [19]. R0 is dependent on population density and
this dependence varies between countries [20]. In this
paper, we attempt to determine this dependence for
Africa and India.
In the following paragraphs, we describe (1) inclusion/
exclusion criteria for the literature we used in our analy-
sis, (2) methods for extracting and summarizing age-
stratified attack rates for Africa and India, (3) methods
for extracting and summarizing age-stratified seropreva-
lence for Africa and India, and (4) methods for comput-
ing the dependence of R0 on population size.
Inclusion/Exclusion criteria
To identify relevant literature sources with useful data,
Web of Science, Google Scholar, and PubMed were
searched using terms including: “case report”, “case
study”, “surveillance”, “epidemiology”, “seroepidemiol-
ogy”, “antibody”, “seroprevalence”,a n dv a r i a t i o n so n
each term combined with the terms: “measles”, “Africa”
or “India”, and sometimes specific country names within
Central or Eastern Africa such as “Nigeria”, “Niger”, and
“Uganda”. The reference section in each paper was
checked and any papers that had referenced them were
also researched. We focussed on identifying papers
dated before the era of widespread vaccination in Africa
and India, i.e., from the 1970s and early 1980s. This is
because vaccination influences infection transmission in
the population and hence can affect seroprevalence and
attack rates [19]. (However, we note that methods do
exist for adjusting for such effects). We included several
more recent papers as well to analyze the changes in
epidemiology as a result of vaccination.
Each source was classified into one of three types: (1)
epidemic case reporting, (2) endemic case reporting, and
(3) seroprevalence. Epidemic case reporting papers gen-
erally describe the percent infected by age during a spe-
cific measles outbreak. Conversely, endemic case
reporting papers describe reported cases over a longer
period of time, during and outside of outbreaks. Case
report studies can suffer from under- or over-reporting
due to misdiagnosis, unreported cases, or subclinical
infection. Seroprevalence studies do not suffer from
under/over-reporting subclinical infection, or misdiagno-
s i sa n dh e n c ec a np r o v ev e r yu s e f u lw h e nt r y i n gt o
determine what proportion of the population remains
susceptible. On the other hand, seroprevalence surveys
do not always reflect long-term average conditions in a
given population. For instance, a seroprevalence profile
obtained just before an epidemic outbreak will differ
from one obtained just after an outbreak, and this can
influence estimates of the mean age at infection and the
force of infection. This is especially a problem for smal-
ler, isolated populations with long inter-epidemic inter-
vals. Moreover, seroprevalence studies cannot
distinguish between immunity due to natural infection
and immunity due to vaccination. We included seropre-
valence publications that used a representative, ran-
domly chosen sample set with a relatively large number
of children in each age category being tested. We
included case report publications that relied on national
surveillance systems or representative community-based
surveys.
Many case report studies that we found only used
hospital data to estimate incidence or attack rates
(eg. [21,22]). Unless some adjustment is made, this may
create a sampling bias towards those children who have
access to health care or those children sufficiently ill to
be admitted to a hospital. Hence, these publications
were excluded. Of the seroprevalence studies, many
were only concerned with seroconversion rates after
vaccination (eg. [23-25]) or collected samples from chil-
dren and infants attending a health care centre (eg.
[26-29]), which again may introduce bias by including
Szusz et al. BMC Research Notes 2010, 3:75
http://www.biomedcentral.com/1756-0500/3/75
Page 3 of 17only those with access to health care. Hence, these pub-
lications were also excluded.
A common occurrence among Indian case report stu-
dies was that the authors would report the number of
cases in an age group but not give a breakdown by age
of the surveyed population, making it impossible to cal-
culate the attack rates (eg. [30-32]). In other publica-
tions, children were surveyed regarding the age when
they had measles infection, but it was unclear when the
population per age group was tabulated, again making
attack rates impossible to calculate (eg. [33-35]).
Reporting and construction of age-stratified attack
rate and seroprevalence profiles
We summarized the age-stratified attack rates from
most included studies through several figures. The
attack rates were either taken directly from the study,
when available for each year of age, or found by calcu-
lating them from component data reported in the study.
If the reported age group spanned more than one year,
then the attack rate reported for the whole age group
was also assumed to represent the attack rate for each
individual year of age in that age group.
Similarly, from the seroprevalence studies, the percent
of children seropositive for measles antibody was taken
directly from the data, when available for each year of
age. If the reported percent seropositive in an age group
spanned more than one year, then the seropositive value
was assumed to represent the percent seropositive of
the midpoint age of the age group only.
To fit a “representative” seroprevalence profile, we
first constructed an average profile from the surveys
reviewed as follows. If only one of the reviewed studies
reported seroprevalence at a given age, then that was
used as the seroprevalence of the average profile at that
age. If more than one reviewed study reported seropre-
valence at a given age, then the average seroprevalence
of those studies–weighted by their sample size–was
used as the seroprevalence of the average profile at that
age according to the equation:
Ss
nij
Ni
ii j
j
 (1)
where Si is the average seroprevalence in age class i, sij
is the seroprevalence in age class i from study j, nij is
the number of samples in age class i of study j,a n dNi
= Σjnij. Finally, if no reviewed study reported seropreva-
lence at a given age, then the seroprevalence of the aver-
age profile was not given for that age. Below age 1,
averaged seroprevalence data points were sought for 3,
6, and 9 months (or as close to that as possible), and it
was assumed that all newborns had maternal immunity.
Above and including age 1, averaged seroprevalence
data points were sought for each year, although they
were not always available, especially for some older ages
where no included studies reported samples from that
age.
This average seroprevalence profile was then fitted to
the following equation to generate a “representative” or
“typical” age-stratified seroprevalence profile:
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k
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where S(a) is the percent seropositive in age a, and k1,
k2 and k3 are constants. The last term exp(-k3a)i n
Equation (2) describes an exponentially declining curve
that captures the decline in seroprevalence attributable
to maternal immunity in the first year of life. The rest
of Equation (2) describes a curve that captures seropre-
valence attributable to infection, where k1 and k2 control
how quickly seroprevalence increases with age and how
high seroprevalence can become in the oldest age
groups. For realistic values of k1 and k2,o n eo b t a i n sa n
S-shaped seroprevalence profile with an inflection point
at young ages, that approaches 100% seroprevalence
asymptotically. By dropping the maternal immunity
term in Equation (2) one can also define the seropreva-
lence attributable to infection as:
SaS a k a
k
k
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These equations were adapted from the approach
described in Ref [36] and references therein. The values
of k1, k2 and k3 that yielded the smallest ordinary least
squares error between S(a) and the average seropreva-
lence profile were deemed optimal and used to con-
struct the representative seroprevalence profile. The
squared error at each age was weighted according to
how many adjacent ages (+/- 1 year) had known average
seroprevalence data points, to mitigate over-sampling of
age ranges for which there were many available average
seroprevalence values. Because Equation (2) accounts
for decay of maternal antibodies, we can fit it to sero-
prevalence data for all age categories, including those
below 1 year of age. Although Equation (1) adjusts for
variable sample sizes across studies within a given age
class, we do not adjust for variable sample sizes across
age classes when fitting Equation (2). We note that this
introduces the potential for wayward estimates of sero-
prevalence to influence the best-fit representative sero-
prevalence profile.
P l o t so fa g e - s t r a t i f i e da t t a c kr a t e sf r o mi n c l u d e ds t u -
dies were constructed for both India and Africa. Sepa-
rate plots were constructed for epidemic versus endemic
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dies for age-stratified seroprevalence surveys for India
and Africa. The representative seroprevalence profile
from Equation (2) was included on the same plot.
Estimation of force of infection
To estimate the force of infection from the average ser-
oprevalence profiles for Africa and India, we formulated
several functions for an age-dependent force of infec-
tion, modelled the seroprevalence profiles resulting from
those functional forms, and fitted the resulting seropre-
valence model to the average seroprevalence profiles for
India and Africa. A catalytic modelling approach adjust-
ing for the presence of maternal antibodies allows us to
relate the force of infection l (a)a ta g ea to seropreva-
lence via:
()
()
() a
Sa
d
da
Sa e
ka 

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 1
1
3 (4)
where k3 is the maternal immunity component emer-
ging from Equation (2). Equation (4) can be discretized
with respect to age, giving:
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where Δa is a (very small) age increment from j-1 to j,
Sj is seroprevalence at age j,a n dlj is the force of infec-
tion at age j. Equation (5) can be solved for Sj yielding
SS a S k e jj j j
kj         

11 3 1 3   . (6)
From Equation (6), the seroprevalence arising from
any assumed force of infection can be derived. The four
functional forms for the force of infection that were
tested were:
() ak   1 constant (7)
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where S(a) and Sinf(a) in Equation (10) are taken from
Equations (2) and (3) according to the seroprevalence
model of Ref [36].
Values of k1, k2 (where applicable), and k3 were tested
with fine resolution across broad ranges and the sum-of-
squares error between the seroprevalence computed
from Equation (6) and the average seroprevalence pro-
files for India and Africa was computed. The criterion for
best fitting parameters was the minimization of sum-of-
squares error. The model parsimony of the linear and
exponential forms relative to the constant forms were
analyzed via an F-test in order to test the hypothesis that
the force of infection declines with age. A declining force
of infection with age would indicate that the eradication
equation pc =1 - 1 / R0 overestimates the required propor-
tion immune for eradication in those populations [19].
T h eF - r a t i oi st h er a t i oo ft h ei n c r e a s ei nt h es u m - o f -
squares error (of the simpler model relative to the more
complex model) to the increase in the degrees of freedom
(of the more complex model relative to the simpler
model). An F-ratio greater than 1 indicates that the more
complex model may be parsimonious.
This method of computing the force of infection was
repeated for each individual age-stratified seroprevalence
profile from the included Indian and African studies,
with the exceptions of Refs [37] and [38] in African
populations, due to lack of data points below 1 year of
age in those surveys. Hence, we computed force of
infection for 6 studies in Indian populations and 2 stu-
dies in African populations, for the exponential and con-
stant functional forms.
Estimation of R0 and relation to population size
Studies have shown that R0 increases with increasing
population density, particularly via:
RK N
c
0  (6a)
where N is the total population, K is a scaling con-
stant, and 0 ≤ c ≤ 1 is a constant that determines the
impact of population density on R0 [20].
The relation between R0 and population size was deter-
mined in both African and Indian populations using case
reporting and seroprevalence data. In Africa, we esti-
mated R0 values for large cities or rural areas in 8 differ-
ent countries, whereas in India, R0 values were estimated
for 11 different urban or rural regions. In one African
study, the R0 value was estimated by averaging over a sta-
tistical description of R0 values reported directly by the
authors and so no further calculation was necessary. For
all others, the R0 value was estimated using the formula:
R
G
AD
0 

(7a)
where G is the inverse of the per capita birth rate, A is
the age at infection in years assuming no vaccination
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maternal antibodies [14]. D = 3.3 months was estimated
from a study by Hartter et al [39]. G was estimated
from demographic data made available in the study or,
if not available in the study, from other various sources.
The mean age at infection A was calculated in two dif-
ferent ways depending on what data were available in
the study. Both methods assume that the populations
have experienced no previous history of vaccination,
which of course is only approximately true in most
cases. Therefore, the following methods estimate the
mean age at infection in a partially vaccinated popula-
tion, A’. If the force of infection (l) was known through
a pre-existing estimate, A’ was estimated via [19]:
A’/ . 1  (8a)
If l was not given, then A’ was estimated via:
 
 

A
ri ai
i
ri
i
(9a)
where ri is the attack rate at age ai.W en o t et h a ti ti s
possible to underestimate A’ using this formula if attack
rates at higher ages are not given [14,18]. Each age was
taken at the midpoint of the year (i.e. ai = 0.5 yr, 1.5
yrs, 2.5 yrs, etc). For case report studies, attack rates
were determined as before. For seroprevalence studies,
the attack rate at age ai above one year of age was esti-
mated as:
SS ii inf, inf,   1 (10a)
where Sinf, i is the proportion seropositive at age ai. The
values of Sinf, i were the best-fit values of Equation (3) to
the data from each individual study, above the age of 1.
Since vaccination can increase the mean age at infec-
tion, the values of A’ computed from a population
where vaccination is occurring must be adjusted before
Equation (7) can be applied. To adjust for vaccination,
we used the following relation between the mean age at
infection A’ with vaccination coverage and the mean age
at infection A without vaccination:
AA p    () 1 (11a)
where p is the percent of the study population with
vaccine derived immunity [19]. To find p,w ef i r s t
sought vaccination coverage data reported specifically
for the populations studied. If this was not given, p was
found using the total vaccination coverage by country
[40] for the study year and the number of years previous
equal to the number of age groups sampled (if possible)
and averaged. We assumed a vaccine efficacy of 85%
[41]. Thus p is just the product of the average vaccine
coverage and vaccine efficacy. The resulting values of A
were used in Equation (7).
Thus, with estimated values of R0 for each population
sampled, and with the corresponding population size N,
we fitted a linear regression to Equation (6), rescaled on
a ln-ln plot, and used ordinary least squares criterion to
obtain the best-fit values for c and K.
Results
Tables summarizing the studies that were included in
the analysis are given in Additional Files 1, 2, 3 and 4.
The first two files describe all included case reporting
studies for Africa and India respectively, and the second
two files describe all included seroprevalence studies for
Africa and India respectively. For each country, the
tables describe the population studied, the year of study,
type of study, study objectives, major conclusions, and
limitations. In the following paragraphs we describe the
studies. The review of these studies is broken down by
region (Indian versus African populations) and study
type (case reporting versus seroprevalence). In the latter
part of the Results we present the analysis of the depen-
dence of R0 on population size.
Case report analysis: Africa
The age-stratified attack rates for African populations
are summarized in Figure 1a (epidemic case reports) and
1b (endemic case reports). The age of peak attack rates
is 1 year in almost all studies where sufficiently fine age
stratification allows this observation to be made. As
already noted, this is a much younger age than observed
in the “developed” world before the advent of mass vac-
cination in the middle 20
th century [14,18].
In Africa, three epidemic studies were analyzed and all
took place within an urban setting. An epidemic took
place in Kampala, Uganda [42] and Niamey, Niger [43]
within the same year but the epidemics exhibited differ-
ent characteristics. Though Kampala had almost twice
the population of Niamey and lower vaccine coverage,
the highest attack rate was found in the 12-23 month
age group, compared to 6-8 months of age in Niamey.
However, Niamey had an overall lower total percent
infected in children under 5 years than in Kampala
(11.65% vs. 16.94%). In 2004, outbreaks were investi-
gated in representative regions in three separate coun-
tries: Nigeria, Niger, and Chad [44]. Comparing attack
rates in Niger between this epidemic and the early epi-
demic in 1990 [43], we see that the reported attack rate
under age 5 is higher. However, out of the three coun-
tries investigated by Grais et al [44], Niger had the low-
est overall attach rate in children less than 5 years.
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countries can be due to a variety of factors including
geographical location, crowding effects, availability of
health care, and changing birth rates which would
change the rate of recruitment of susceptible individuals
[45]. And even though vaccine coverage may seem quite
high (73% in Niamey, 1990), there may be a high vac-
cine failure rate due to poor maintenance of the cold
chain or because vaccinations were given to children
already immune, or were given at the incorrect age [46].
F o u re n d e m i cc a s er e p o r t i n gp u b l i c a t i o n sw e r ea l s o
reviewed, three within an urban setting [46-48] and one
in a rural setting [49]. In both the rural and urban set-
tings, the highest attack rate was seen within the 6-11
month age group except in one study which reported
the highest attack rate in children 9-23 months [47].
The papers by Guyer et al [46] and Heymann et al [47]
combined describe the epidemiology of measles over a
period of ten years within the city of Yaoundé, Camer-
oon. Yaoundé experienced a continuous decline in
attack rates in all age groups from 1972 to 1979, even
though surveillance was increased in 1974 and then
again in 1977. There was a large decrease in attack rates
in the younger age groups, but also a smaller decrease
in older age groups, suggesting a possible herd immu-
nity effect. Heymann et al report constant vaccination
coverage of roughly 40% over most of this time; consis-
tent vaccine coverage may have led to the decline in
attack rate. The discrepancy between the two papers for
attack rates in 1975 could be due to how the authors
estimated the population per age group. Taylor et al
[48] reported on Kinshasa, Zaire (now known as the
Democratic Republic of the Congo) several years after
Heymann et al published their paper. The cumulative
percent infected calculated from their data showed a
slightly higher percentage in children less than 1 year
but lower in all age groups above that. Though Kinshasa
had a much higher population than Yaoundé, they had a
continual increase in vaccination coverage from 1977 to
1983 which probably allowed for a decrease in attack
Figure 1 Percent infected by age for outbreak and endemic studies. The value shown at age 0 actually represents all children under the
age of 1 year. Flat lines indicate an attack rate for an age group that spans more than one age. a) Epidemic studies in Africa. b) Endemic studies
in Africa. c) Epidemic studies in India. d) Endemic studies in India.
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et al explain that there was non-uniform vaccination
throughout the city, which left pockets of susceptible
individuals, allowing for continuing transmission despite
overall high vaccine coverage. Furthermore, children
under 9 months may have served as a reservoir for
measles transmission because most were too young to
be efficaciously vaccinated but had a high incidence
rate. Although vaccinating at a younger age may suggest
i t s e l fa sas t r a t e g yt oc o m b a tt h i s ,t h ev a c c i n ei ss i g n i f i -
cantly less efficacious below 9 months of age due to
interference from maternal antibodies, and vaccinating
to sufficient levels in older age groups can provide herd
immunity that protects younger age groups [43].
Case report analysis: India
Figure 1c (epidemic) and 1d (endemic) summarize the
age-stratified attack rates for various Indian populations.
From the studies that are stratified by year, the highest
attack rate lies roughly between 1 and 2 years of age,
which is slightly higher than that noted in the African
populations but still lower than in developed countries
in the mid-twentieth century. Furthermore, the most
recent studies in each figure show that the peak attack
rates have shifted to the older age groups. This may
reflect changing demographics, social circumstances, or
improving vaccine coverage.
Three endemic papers were analyzed for India. Garai
et al [50] and Jain et al [51] both conducted commu-
nity-based surveys in rural areas over a period of three
years. Of the two, Jain et al indicated a distinctive lower
cumulative % infected at every age up to age 14 yrs.
Many factors could have influenced this, such as geo-
graphic location or timing of epidemics, but because
both studies spanned three years a more likely cause is
a higher vaccination coverage seen in the population
studied by Jain et al. Though vaccination coverage was
not mentioned in either paper, we know that mass rou-
tine immunization did not start until the mid 1980s so
it is quite possible that Garai et al studied an almost
vaccine free population while Jain et al were able to
study a population with at least some vaccination. Bhas-
karam et al [52] showed a higher cumulative % infected
despite being conducted in between the previous two
studies. However, their study was conducted in an
urban slum and so crowding effects may have caused an
increase in the number of children infected. Also, the
study was conducted over a period of one year, so it is
possible that it was an epidemic year.
We were able to find six outbreak papers for India
[53-58], all within a rural setting with minimal or no
vaccination at all, except Gupta et al [58]. There does
not seem to be variation in the attack rates across vary-
ing vaccination coverage levels or population sizes. This
is also seen in the paper by Narain et al [56] who sur-
veyed 13 unvaccinated villages, where both large and
small villages experienced high attack rates. Isolated
populations can experience only intermittent but large
outbreaks of measles that may be more difficult to pre-
dict [59], so the apparent lack of clear dependence on
vaccine coverage or population sizes may reflect lesser
predictability of measles outbreaks in rural populations.
In all papers except Gupta et al, the highest attack rate
during the outbreak was in children below the age of 4
years. Gupta et al was the only paper to have an increas-
ing percent infected by age group, the lowest being in
children 0-4 years and the highest being in children 10-
14 years.
T h o u g hC h a n de ta l[ 6 0 ]w a sn o ti n c l u d e di nt h e
table, we felt it necessary to discuss as it does give over-
all attack rates for children under 14 years of age and
for the entire population of a representative village over
a period of thirteen years. Before 1980, epidemics
occurred every 2 years at varying levels of intensity, but
after 1980, the inter-epidemic period lengthened to 3
years. This transition from outbreaks every 2 years to
outbreaks every 3 years may reflect the introduction of
vaccination [61]. It can also be seen that during the last
3 years of the study, the fluctuations in incidence rates
becomes less dramatic. The authors suggest that these
changes in the outbreak patterns of the disease were a
result of the Measles Vaccination Programme.
Seroprevalence analysis: Africa
We identified five studies that give a reasonable to
excellent age breakdown of seroprevalence in African
populations; however we only included the three oldest
in Figure 2a since they were likely to have limited vacci-
nation coverage and thus reflect exposure to natural
infection rather than immunization [62-64]. These three
were thus used to estimate an average seroprevalence
profile. The average seroprevalence profile computed
from these studies indicates that about 60% of children
exhibited seropositivity for m e a s l e sa n t i b o d yb yt h ea g e
of 2. Figure 2b shows the age-dependent force of infec-
tion as computed from the representative seroprevalence
profile in Figure 2a, using Equation (5).
There was considerable variation in seroprevalence by
age across the studies although it was quite evident that
the two more recent studies [60,37] showed a much
higher seroprevalence rate among children over 1 year
old. This is most likely due to increased vaccination
(~80% in Addis Ababa and national coverage of 55% in
Eritrea prior to when the study was carried out), but
perhaps also the fact that both were conducted in an
urban setting where crowding effects occur. The two
older urban studies [63,64] both show a low seropositiv-
ity in children aged 1 to 5 years, but Munube et al [38]
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reported by Enqusellassie et al [37]. This could be due
to sampling location or the fact that their sample size
was smaller than all the others. Unfortunately, vaccine
coverage was not available in most studies, so we could
not compare vaccine coverage to seroprevalence more
systematically. All of these studies were in urban popu-
lations, except for a district-wide survey in Busoga dis-
trict, Uganda, which included rural populations [38]. As
noted in the Methods section, seroprevalence profiles
can be less representative of average conditions in cases
where measles epidemiology is characterized by inter-
mittent outbreaks, as might occur for some isolated
rural populations.
Seroprevalence analysis: India
We identified 6 seroprevalence studies in Indian popula-
tions [65-70], all conducted in an urban setting and
published in the 1970s or early 1980s (Figure 2c). Sero-
prevalence increases less quickly with age than in the
African studies, as seen in the modelled average seropre-
valence curves. This suggests that the force of infection
is higher at younger ages in African populations. How-
ever, the lowest seroprevalence occurs at the age of 8
months in both India and Africa, demonstrating similar
waning patterns of maternal antibodies. Because all
these studies were in urban populations, the lack of
representativeness of the seroprevalence profile that can
be caused by intermittent outbreaks in small, isolated
populations should not be an issue here (see Methods).
Figure 2d shows the age-dependent force of infection as
computed from the representative seroprevalence profile
in Figure 2c, using Equation (5).
Seroprevalence data do not usually distinguish
between immunity from infection and immunity from
vaccination but since mass routine vaccination did not
Figure 2 Seroprevalence and force of infection by age. a) Representative seroprevalence profile for Africa. The parameters for the best-fit
average seroprevalence profile are k1 = 0.56, k2 = 0.46 and k3 = 2.64. b) Force of infection in Africa, computed from representative
seroprevalence profile for Africa (panel 2a) using Equation (5). c) Representative seroprevalence profile for India. The parameters for the best-fit
average seroprevalence profile are k1 = 0.63, k2 = 0.58, k3 = 2.62. d) Force of infection in India, computed from representative seroprevalence
profile for India (panel 2c) using Equation (5).
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us a good picture of how prevalent measles would be
without vaccination, at least within an urban setting
during those decades.
In almost all of the studiesi nI n d i a np o p u l a t i o n s ,
r o u g h l y8 0 %o fc h i l d r e na r es e r o p o s i t i v eb ya g e6y e a r s .
The exception is Sehgal et al. [69], which incidentally
had the highest sample size. In most papers, seropreva-
lence could either increase or decrease from one age to
the next. This could be evidence of a cohort effect
[71,72], but is more likely a sample size effect. Interest-
ingly, Sehgal et al was the only paper not to exhibit this
effect, again perhaps because of its large sample size.
Khare et al [70] report a lower seroprevalence in chil-
dren under 9 months but a higher seroprevalence above
9 months, compared to other studies. This study is rela-
tively recent and thus its higher seroprevalence at
younger ages could reflect the initial effects of vaccina-
tion. Vaccination also shifts incidence to older children
due to herd immunity, which protects younger children
from acquiring measles infection. From the seropreva-
lence profile, we see that below the age of 8 months, the
majority of the seroprevalence will be from maternal
antibodies that continually decline. The rise again in ser-
oprevalence after 8 months is then due to the acquisi-
tion of measles infection, or vaccination.
Estimation of force of infection
Table 1 gives the best-fitting parameter values for the
four force of infection functions fitted to the average
seroprevalence profiles for Africa and India. Also shown
are the results of the F-test for comparing the exponen-
tial and linear force of infection functions to the con-
stant force of infection function. The minimum sum-of-
squares error is smaller under the exponential and linear
functions (wherein the force of infection declines with
age at best-fit parameters for both functions) than the
constant function. Also, the F-ratios are larger than 1
for the linear and exponential functions for the Indian
seroprevalence profile, implying that the linear and
exponential functions with declining force of infection
with age are more parsimonious (explain the data bet-
ter) than the constant function where force of infection
does not decline with age. These results imply that the
force of infection may decline with age in Indian popu-
lations of this time period. F-ratios for the African sero-
prevalence profile are smaller than 1, hence there is not
strong evidence for a declining force of infection in the
surveyed African populations of that time. The best-fit-
ting force of infection functions for both African and
Indian seroprevalence profiles appear in Figure 2b, d.
Table 2 gives the results of the F-test for the 8 indivi-
dual seroprevalence surveys, for comparing the expo-
nential function to the constant function only. The
F-ratio is greater than 1 in 5 of the 6 Indian seropreva-
l e n c es u r v e y s ,b u tt h eF - r a t io is less than 1 in both of
the 2 African seroprevalence surveys. This again sug-
gests that the force of infection declines with age in
these Indian populations at the time of the survey.
The unimodal force of infection predicts an increase
in the force of infection with age, followed by a
decrease. We note that the eradication equation pc =
1-1/R0 overestimates the critical proportion of immune
only if the force of infection declines beyond the mean
age at infection. For the exponential and linear functions
which decline monotonically with age, this condition is
automatically satisfied. However, for the unimodal func-
tion, it is only satisfied if the mean age at infection
exceeds the age of peak force of infection. At the best-
fit parameter values for the unimodal function for the 6
Indian and 2 African seroprevalence surveys of Table 2,
this condition is always satisfied (results not shown).
Table 1 Fit of seroprevalence data to seroprevalence
model under different force of infection (FOI) functions
Africa
FOI
Function
Best-fit
k1
Best-fit
k2
Best-fit
k3
Least sum-of-
squares
F
ratio
Constant 0.315 –* 3.59 0.042 –
Linear 0.377 0.055 3.56 0.036 0.33
Exponential 0.427 0.108 3.58 0.034 0.48
Unimodal 0.532 0.452 2.88 0.044 – **
India
FOI
Function
Best-fit
k1
Best-fit
k2
Best-fit
k3
Least sum-of-
squares
F
ratio
Constant 0.275 –* 2.97 0.0185 –
Linear 0.410 0.103 3.16 0.0058 4.33
Exponential 0.468 0.199 3.26 0.0059 4.25
Unimodal 0.598 0.568 2.81 0.0077 2.76
*No k2 parameter in function.
** An F ratio was not computed because least sum-of-squares was greater
than the constant case.
Table 2 F test results from individual seroprevalence
studies for exponential versus constant force of infection
function
Study City F ratio
Mehta et al 1972 [65] Bombay, India 0
John and Jesudoss 1973 [66] Vellore, India 2.44
Broor et al 1976 [67] Chandigarh, India 3.86
Bhau et al 1979 [68] Pondicherry, India 2.62
Sehgal et al 1983 [69] Delhi/Alwar, India 0
Khare et al 1987 [70] Delhi, India 1.25
Stanfield and Bracken 1971 [62] Kampala, Uganda 0.46
Ogunmekan et al 1981 [63] Lagos, Nigeria 0
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The following populations in Africa were used to deter-
mine the relationship between R0 and population size:
Niakher (Senegal, 1983-2001) [73], Niamey (Niger,
2003-2004) [74], Machakos (Kenya, 1984) [17], Moshi
(Tanzania, 1984) [17], Kinshasa (Zaire, 1983) [48], Kam-
pala (Uganda, 1990) [42], Yaoundé (Cameroon, 1971,
1975) [46], and Lusaka (Zambia, 1996-1999) [75].
Data required to calculate R0 are summarized in Table 3
and a log-log plot of R0 versus N is given in Figure 3a
whose slope is the constant c in Equation (6). The first
two studies were the only two to provide R0 estimates in
the publication or estimates of the mean age at infection.
The R0 = 9.6 value for Niamey was found by averaging
over all R0 values reported for various districts of the city.
For Niakher, Broutin et al reported a mean age at infection
(with no vaccination coverage) of 4.6 years and a per
capita birth rate of 47/1000 giving an R0 value of 4.9. (The
authors also estimated R0 but did not adjust for maternal
immunity).
Equation (8) was used to find A’ in Machakos, Moshi
and Lusaka, and Equation (9) was used for the rest of
the studies. Seroprevalence studies were not included
due to the relatively few studies with sufficiently good
age stratification to allow computation of A. The study
by Enquselassie et al [37] was also not included because
their data incorporated a high proportion of vaccinated
individuals in all age groups. The recommended age for
vaccination is 9 months and so vaccinated populations
have a very high seropositivity rate from a very young
age which would misrepresent the actual seroprevalence
due to natural infection. Birth rates were reported in the
studies for Yaoundé and Lusaka, but for the most part,
birth rates were found from various other sources. Vac-
cination coverage for each study population was
reported in all papers except Taylor et al and Scott et
al. For those two studies, estimates from the World
Health Organization (WHO) website were used to cal-
culate p. R0 values were calculated and reported in
Table 3. The unusually high value of R0 for Yaoundé,
Cameroon, 1971, may reflect the fact that only cases
below the age of 3 were reported (though these consti-
tuted 90% of all cases, according to the authors). The
best fit value of a linear regression to a plot of log(R0)
versus log(N) yielded c = 0.1708, the R
2 value was 0.051,
and the P < 0.6. This P-value suggests that it is more
likely that there is no relation between population and
R0; however, we sampled over many different African
countries so it is possible that this relation would be
stronger within individual countries.
R0 estimates: India
We estimated R0 values for 11 different regions in India:
Sathuvachari village (Tamil Nadu, 1969) [53], Ramgarh
village (Rajasthan, 1986-1988) [51], Hyderbad city
(Andhra Pradesh, 1982-1983) [52], Hooghly District
(West Bengal, 1976-1978) [50], 13 villages of Tehri
Garhwal (Uttar Pradesh, 1986) [56], Dumehar village
(Himachal Pradesh, 2004) [58], Barbadi (Maharashtra,
1982) [54], Bombay (Maharashtra, 1972) [65], Vellore
(Tamil Nadu, 1973) [66], Pondicherry (Puducherry,
1979) [68], and Delhi (1984-1985) [70].
The key values needed to determine R0 values are
summarized in Table 4 and Figure 3b gives the log-log
plot of R0 versus N. For every study population, Equa-
tion (9) was used to determine the mean age at infection
with vaccination. Equation (11) was then applied to find
A. The first 7 studies were case report studies and so
the mean age at infection was calculated directly from
the attack rates. The last 4 were seroprevalence studies
so Equation (3) was used first to fit the data to ensure
non-negative attack rates. Birth rates were obtained
through correspondence with a member of the Popula-
t i o nR e f e r e n c eB u r e a u .T h eb i r t hr a t e sw e r eg i v e nb y
state and so it was assumed these birth rates accurately
represented the birth rates for each village or city stu-
died. The duration of immunity due to maternal antibo-
dies was assumed to be the same as that in Africa. This
was justified earlier in the analysis of seroprevalence in
India where it was noted that both India and Africa
Table 3 Summary of key values needed to determine R0 values for Africa
City/Country Birth Rate pA ’ AN R 0
Niamey/Niger [74] n/a* n/a n/a n/a 750000 9.5641
Niakher/Senegal [73] n/a* n/a n/a n/a 23413 4.9194
Machakos/Kenya [17] 43/1000 [77] 0.2784 2.9070 2.0977 84320 [78] 12.7587
Moshi/Tanzania [17] 50.5/1000 [79] 0.0000 3.1153 3.1153 96838 [78] 6.9719
Kinshasa/Zaire [46] 49/1000 [80] 0.2040 1.6078 1.2798 3000000 20.3101
Kampala/Uganda [40] 50.1/1000 [79] 0.4080 2.5355 1.5010 800000 16.2804
Yaounde/Cameroon 1971 [44] 45/1000 0.6053 0.9736 0.3843 166000 203.3308
Yaounde/Cameroon 1975 [44] 45/1000 0.4316 1.0522 0.5981 260000 68.7812
Lusaka/Zambia [75] 40/1000 0.7395 5.0000 1.3025 1240000 24.3309
*n/a = not applicable since authors report A or R0 directly
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Only 3 out of the 11 studies reported vaccination cover-
age. For all others it was either assumed that there was
no vaccination coverage due to the timing of the study or
it was specifically stated in the paper. Populations were
either given in the study or found from websites as close
to the time of the study as possible. The resulting best-fit
value of c was 0.0813, the R
2 value was 0.2285, and the P
< 0.14. This P-value is lower than that for Africa, suggest-
ing that it is likely that the relationship between R0 and
population is stronger within a country [20], despite the
heterogeneity in conditions across Indian states.
Discussion
Although the quality of data for low-income countries
varies widely, as do epidemiological patterns, several
Figure 3 Plot of log(R0) versus log(N) to determine the value of c. a) Linear regression for Africa. R
2 = 0.051, P < 0.6. b) Linear regression for
India. R
2 = 0.2285, P < 0.14.
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analysis. Firstly, this review confirms previous findings
that the mean age of infection and age of peak attack
rate, are significantly lower in African and Indian popu-
lations than was common in Western countries before
the advent of mass vaccination [14,18]. This kind of
information can be used to parameterize dynamic mod-
els for low-income countries, and suggests that some
interesting differences may emerge between model pro-
jections for Western countries and those for low income
countries.
A classical result of epidemiological theory is that the
critical proportion immune required to eradicate an
infectious disease equals 1 - 1/R0. For populations where
the force of infection declines with age, this is an over-
estimate of the critical threshold required to eradicate a
disease, because it assumes homogeneous mixing across
ages [19]. Intuitively, this effect occurs because vaccina-
tion increases the mean age at infection, so if the force
of infection decreases with age, the impact of vaccina-
tion is multiplied as vaccination pushes infection events
to older ages where the force of infection is lower [19].
The results of Tables 1 and 2 suggest that the eradica-
tion equation pc = 1-1/R0 may overestimate the propor-
tion of individuals that need to be vaccinated in order
to eradicate measles in at least some populations low-
income countries. This issue may not be important for
models of measles in developed Western populations,
where the force of infection climbs, peaks between ages
5 and 15, and then declines, making it difficult to know
ap r i o r ithe direction of bias introduced by using the
equation pc =1-1 / R0. However, we also note that
other aspects of real populations, such as spatial and
social heterogeneity, could conceivably make measles
eradication more difficult than suggested by either age-
structured or homogeneous compartmental models.
As vaccination decreases transmission and thereby
increases the mean age at infection, transmission
dynamics in older age classes can become an important
factor in determining the effectiveness of immunization
programmes. Because of this, reliable data on seropreva-
lence in older age classes is needed to accurately esti-
mate force of infection in these classes. However,
obtaining such reliable data can be difficult because the
vast majority of individuals are infected at a young age,
which introduces sample size issues for inferring force
of infection at older ages. In these cases, quality of the
data becomes more important. However some assays
may have poor sensitivity which could lead to underesti-
mating seroprevalence. If the force of infection is esti-
mated using insufficient or poor quality data in older
age classes, and is used to parameterize the age-specific
transmission rates of an age-structured compartmental
model [19], there is a significant possibility of erroneous
predictions.
This literature review produced R0 estimates that vary
widely across various populations, from 4 to 26.
Although the data upon which these estimates are based
are generally limited in quality, estimates from other
populations for which better data are available also indi-
cate significant variability in R0 estimates for measles
[19], and so this outcome is not unexpected.
The attack rates in African populations studied peak
at age 1 for both rural and urban areas, although studies
from later years when vaccination coverage is higher
tend to indicate later peaks. According to the average
seroprevalence profile estimated with a model from
populations with little or no vaccination, roughly 60% of
children are seropositive by age 2.
In the Indian populations studied, the attack rates
peak between 1 and 2 years, which is somewhat higher
than for African populations studied. Newer studies also
Table 4 Summary of key values needed to determine R0 values for India
City/Region Birth Rate pA ’ AN R 0
Sathuvachari [51] 31.4* 0.2010 2.2401 1.7898 1200 21.4339
Ramgarh [49] 36.2 0.0468 4.4506 4.2426 5258 6.9243
Hyderbad [50] 30.8 0 2.2401 2.2401 3,043,896 [78] 16.5221
Hooghly District [48] 35.2** 0 4.7190 4.7190 57267 6.3927
Tehri Garhwal [54] 37.5 0 7.4924 7.4924 349 3.6948
Dumehar village [56] 19.2 0.2870 10.6615 7.6017 1360 7.1087
Barbadi [52] 29.8 0 2.3353 2.3353 1434 16.2875
Bombay [65] 32.2 0 3.3733 3.3733 5,970,575 [81] 10.0237
Vellore [66] 30.0 0 1.7155 1.7155 171157 [78] 23.1407
Pondicherry [68] 29.0 0 2.4465 2.4465 604,471 [78] 15.8800
Delhi [70] 31.0 0 1.5001 1.5001 6,220,406 [78] 26.3316
*birth rate was listed for 1971, study was done in 1969
**value was extrapolated from graph of birth rate vs. year
***values for A’ differ slightly from those in Table 3 due to differing age ranges used in calculation
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The average seroprevalence profile calculated for India
also shows that roughly 55% of children are seropositive
by age 2, which is slightly lower than for the average
African seroprevalence. Hence, both case reporting and
seroprevalence surveys suggest a lower force of infection
in most Indian populations than in most African popu-
lations of the time.
A distinct difference in epidemiological patterns
between rural and urban areas also emerged in this
review. The studies in rural areas are more highly vari-
able in terms of attack rates, often with no obvious
dependence on population size or vaccination coverage.
This is consistent with the projections of dynamic
measles transmission models that exhibit highly variable,
apparently unpredictable outbreaks in small isolated
populations, but relatively more regular patterns in
dense urban populations [59].
Though case report studies are relatively easy to carry
out and can give a general picture of the epidemiology
of measles, they also exhibit several general weaknesses.
For instance, Munube et al [38] point out that many
people believe measles can be acquired more than once
in a lifetime. This belief stems mainly from the fact that
young children are more prone to diseases with similar
symptoms to measles, resulting in misdiagnosis in stu-
dies relying upon self report. (This can also mean that
children are likely to go unvaccinated because it appears
that natural infection cannot cause permanent immu-
nity). This concern has also been discussed in a paper
by DeFrancisco et al who conducted a study in rural
Bangladesh [76]. They explain that over-reporting is
quite common because parents or guardians misdiag-
nose their child’s disease. Conversely, the Indian studies
we reviewed usually exhibited better reliability of case
reports: Mehta et al [65] and Khare et al [70] both show
a strong correlation between positive history of measles
and seropositivity of measles antibody; however, Khare
et al also note that roughly half of those with a negative
history of measles are also seropositive. They speculate
that this is likely due to subclinical infection as well as
misdiagnosis but they also did not rule out the possibi-
lity of lingering maternal antibody effects in young chil-
dren. Thus, seroprevalence studies are a very useful tool
when developing a model of measles transmission since
misdiagnosis and subclinical infection are not proble-
matic. However, seroprevalence studies are generally not
longitudinal, and only give a snapshot of seroprevalence
at a given point in time.
A problem in many of the case report papers for both
Africa and India was that cases were only reported in
very young children in the older papers. In more recent
papers, a fine age breakdown was not provided: this may
reflect sample size issues, as measles tends to be more
rare in more recent times, and case numbers tend to be
smaller in rural populations (as was the case in many
Indian studies). This caused difficulty in trying to dis-
cern any patterns or trends. Attack rates in older chil-
dren are needed to accurately parameterize the force of
infection in older children and thus more accurately
describe herd immunity effects. Thus there is a need for
studies that sample a larger population and at larger
and finer age ranges.
For African populations, patterns in seroprevalence
were difficult to determine due to the lack of available
seroprevalence studies done in Africa. A caveat that
appeared several times in the seroprevalence studies for
b o t hA f r i c aa n dI n d i aw a st h a tn o te n o u g hc h i l d r e n
were sampled in one or more age groups, giving an
inaccurate view of seroprevalence within an age group.
Another problem encountered in some African papers
was that the percent seropositive would be given in an
a g eg r o u pt h a ts p a n n e dm o r et h a no n ea g ea n ds oi t
was necessary to assume that the percent seropositive
applied to the midpoint of the age range. This limited
the number of samples that could be used to calculate
the average seroprevalence in an age group. Finally,
there was variation among the tests for antibody as to
what level was considered positive for protective levels
of antibody. Some studies reported the number of indi-
viduals exhibiting protective levels of antibody whereas
others reported the number of individuals exhibiting any
antibody; this clearly influences how exposure to the
infection is inferred from reported percent seropositive
at a given threshold.
Though the calculations for R0 for both India and
Africa yielded values for the overcrowding exponent c
that are similar to values found in population centres in
England and Wales [20], their R
2 values and P-values
suggest that the observed relation is not statistically sig-
nificant. The large scatter observed in the plots may
reflect unknown vaccination status in many children,
limited data, lack of seroprevalence studies in Africa,
and greater heterogeneity in populations included in the
regression as compared to the relative homogeneity of
populations across England and Wales.
Conclusions
Here we have confirmed previous findings of significant
differences in measles epidemiology in low-income ver-
sus developed countries, with a distinctly lower mean
age at infection in African and Indian populations,
where the age of peak attack rates occurs at age 1 or 2
years [14]. Thus, with the data available in the published
literature, it would be possible to parameterize an infor-
mative dynamic model for measles in African and
Indian populations. However, the quality of data in low-
income countries still lags behind that in developed
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Page 14 of 17countries, and there is a need for more accurate epide-
miological data in low-income countries. We were not
able to show a statistically significant relationship
between population density and the basic reproductive
ratio R0, however, this may reflect other heterogeneities
due to the broad sampling of populations used in the
analysis. Finally, estimation of force of infection func-
tions from age-stratified seroprevalence data suggest
that the force of infection may decline monotonically
with age in those populations, meaning that the eradica-
tion equation pc = 1-1/R0 may overestimate the required
proportion of immune individuals for measles to be era-
dicated in those populations.
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